<DOC>
	<DOCNO>NCT01049438</DOCNO>
	<brief_summary>This clinical trial test hypothesis body decolonization patient recurrent community-associated ( CA ) MRSA infection significantly reduce likelihood recurrent CA-MRSA infection .</brief_summary>
	<brief_title>A Prospective Trial Nasal Mupirocin , Hexachlorophene Body Wash , Systemic Antibiotics Prevention Recurrent Methicillin Resistant Staphylococcus Aureus Infections</brief_title>
	<detailed_description>Staphylococcus aureus ubiquitous pathogen , cause infection skin , lung , bloodstream , body part . Over past decade , community-acquired methicillin resistant S. aureus ( CA-MRSA ) infection , previously extremely rare , occur commonly worldwide . CA-MRSA common cause skin infection many locale U.S. CA-MRSA strain notable ability spread close setting cause recurrent infection among healthy person . Management recurrent CA-MRSA infection challenge optimal prevention strategy undefined . Many expert recommend topical agent decontaminate body and/or anterior naris . However , data quantify efficacy safety approach . We conduct prospective non-comparative clinical trial quantify efficacy safety body decolonization regimens prevention CA-MRSA infection Infectious Diseases private practice group Northern California . The study population comprise person suffer recurrent CA-MRSA infection . For clinical trial , subject give : nasal mupirocin ( Bactroban Nasal , twice daily ) , topical 3 % hexachlorophene body wash ( Phisohex , daily ) , oral anti-MRSA antibiotic . The choice oral antibiotic base investigator choice antibiotic susceptibility prior MRSA isolate give patient . Patients interview person baseline phone 2 week , 3 month , 6 month use standardized questionnaire . The baseline survey , base previously develop instrument use epidemiologic investigation MRSA ask MRSA risk factor health-related quality life . Follow survey ask adverse drug effect , especially gastrointestinal dermatologic side effect ( 2 week visit ) incident skin MRSA infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Staphylococcal Skin Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Mupirocin</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Hexachlorophene</mesh_term>
	<criteria>recurrent MRSA infection great equal 2 MRSA infection 6 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>MRSA</keyword>
	<keyword>Methicillin Resistant Staphylococcus aureus</keyword>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>Skin Infections</keyword>
	<keyword>Body Decolonization</keyword>
</DOC>